Megan Ksenzakovic is the contingent workforce lead for Bristol Myers Squibb, overseeing the company’s CW program, which operationally reports into talent acquisition and HR but has a strong partnership with procurement. She has worked in staffing for 21 years.

Ksenzakovic leads efforts to strategically align contingent labor to the overall Total Talent Strategy, offering additional talent and staffing strategies across all areas of the BMS business. Most recently, the team was engaged to support work for the Cell Therapy group. The team crafted two tailored models to support the bi-coastal business needs, onboarded IT project resources and established a process to support long-term engagement of resources in the manufacturing and quality space.

Ksenzakovic emphasizes that contingent labor become much broader and more strategic now, capable of supporting complex corporate workforce plans. Further, she maintains it’s important to make CW programs “easier and more robust for our end users to engage and for the niche suppliers to want to participate.”

BMS merged with Celgene in November 2019 and is currently integrating two large programs; next steps include a re-launch of the program as a center of excellence, support for all of the BMS D&I commitments, additional global expansions, exploration of new program services and offerings, and bringing the nonemployee workforce into the mainstream of the total talent strategy conversation.